Metolar 3D 50 Tablet ER is a combination antihypertensive medication containing Chlorthalidone (12.5 mg), Metoprolol Succinate (50 mg), and Telmisartan (40 mg). This formulation is designed for extended-release administration to provide sustained blood pressure control in patients with hypertension. Chlorthalidone, a thiazide-like diuretic, promotes natriuresis and diuresis, reducing plasma volume and peripheral vascular resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and reducing myocardial oxygen demand. Telmisartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and decreased sodium retention. The combination targets multiple pathophysiological mechanisms involved in hypertension, offering enhanced efficacy compared to monotherapy. Metolar 3D 50 Tablet ER is indicated for the management of essential hypertension, particularly in patients requiring combination therapy for optimal blood pressure control. It is contraindicated in patients with hypersensitivity to any component, severe renal or hepatic impairment, or pregnancy. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy to ensure safety and therapeutic effectiveness.